Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions

References

• Inzucchi SE. Diagnosis of diabetes. N Engl J Med. 2012;367(6):542–550.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Webb DR, Yates T. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgrad Med J. 2016;92:63–69.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Classification of diabetes mellitus. 2019.
   Google Scholar
• Association AD. Classification and diagnosis of diabetes: standards of medical care in Diabetes 2018. Diabetes Care. 2018;41:S13–S27.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017;13:385–399.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Donner T. Insulin – pharmacology, therapeutic regimens and principles of intensive insulin therapy. Endotext. MDText.com, Inc. 2000. [cited 2020 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25905175
   Google Scholar
• Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• The UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–788.
   PubMed Web of Science ®Google Scholar
• Tamás G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001;54:105–114.
   PubMed Web of Science ®Google Scholar
• Valle D, Santoro D, Bates P. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with type 1 diabetes. Diabetes Nutr Metab Clin Exp. 2001;14:126–132.
   PubMedGoogle Scholar
• Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11:11–17.
   PubMedGoogle Scholar
• Fullerton B, Siebenhofer A, Jeitler K. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;2016:CD012161.
   PubMed Web of Science ®Google Scholar
• Melo KFS, Bahia LR, Pasinato B. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: A systematic review and meta-analysis 11 Medical and Health Sciences 1103 Clinical Sciences. Diabetol Metab Syndr. 2019;11:2.
   Web of Science ®Google Scholar
• Fullerton B, Siebenhofer A, Jeitler K. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12:CD013228.
   PubMed Web of Science ®Google Scholar
• Nicolucci A, Ceriello A, Di Bartolo P. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Ther. 2020;11:573–584.
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25:2053–2057.
   PubMed Web of Science ®Google Scholar
• Homko C, Deluzio A, Jimenez C. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003;26:2027–2031.
   PubMed Web of Science ®Google Scholar
• Di Bartolo P, Pellicano F, Scaramuzza A. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. [ [Internet]]. 2008 [cited 2020 Sep 5];10:495–498.
   PubMed Web of Science ®Google Scholar
• Bode B, Weinstein R, Bell D. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care. 2002;25:439–444.
   PubMed Web of Science ®Google Scholar
• Dreyer M, Prager R, Robinson A. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005;37:702–707.
   PubMed Web of Science ®Google Scholar
• Becker RHA, Frick AD, Burger F. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes. 2005;113:435–443.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Spitzer H. Insulin glulisine: A faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9:746–753.
   PubMed Web of Science ®Google Scholar
• Arnolds S, Rave K, Hövelmann U. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2010;118:662–664.
   PubMed Web of Science ®Google Scholar
• Luzio S, Peter R, Dunseath GJ. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Res Clin Pract. 2008;79:269–275.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Luzio S, Marzotti S. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2011;13:251–257.
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabet Med. 2000;17:762–770.
   PubMed Web of Science ®Google Scholar
• DeVries JH, Lindholm A, Jacobsen JL. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med. 2003;20:312–318.
   PubMed Web of Science ®Google Scholar
• Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes Obes Metab. 2020;22:743–754. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Heise T, Linnebjerg H, Coutant D. Ultrarapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22:1789-1798.
   Web of Science ®Google Scholar
• Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a canadian perspective. Can J Diabetes. 2019;43:515–523.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Bode BW, De Block C. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40:943–950. American Diabetes Association Inc
   PubMedGoogle Scholar
• Mathieu C, Bode BW, Franek E. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab. 2018;20:1148–1155.
   PubMedGoogle Scholar
• Buse JB, Carlson AL, Komatsu M. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab. 2018;20:2885–2893.
   PubMedGoogle Scholar
• Rodbard HW, Tripathy D, Vidrio Velázquez M. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes Obes Metab. 2017;19:1389–1396.
   PubMed Web of Science ®Google Scholar
• Bowering K, Case C, Harvey J. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care. 2017;40:951–957.
   PubMed Web of Science ®Google Scholar
• Klaff L, Cao D, Dellva MA. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22:1799-1807.
   PubMed Web of Science ®Google Scholar
• Blevins T, Zhang Q, Frias J. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D. Diabetes Care. 2020;43:2991-2998.
   PubMedGoogle Scholar
• Cengiz E, Bode B, Van Name M. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016;13:57–69.
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11:372–378.
   PubMed Web of Science ®Google Scholar
• Laranjeira FO, de Andrade KRC, Figueiredo ACMG. Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One. 2018;13:e0194801.
   PubMedGoogle Scholar
• Horvath K, Jeitler K, Berghold A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2007:CD005613.
   PubMedGoogle Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis. Diabetes Res Clin Pract. 2008;81:184–189.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Di Marchi RD, Park GD. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151–1167.
   PubMed Web of Science ®Google Scholar
• Levien TL, Baker DE, White JR. Insulin glargine: A new basal insulin. Ann Pharmacother. 2002;36:1019–1027.
   PubMed Web of Science ®Google Scholar
• Koehler G, Treiber G, Wutte A. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2014;16:57–62.
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med. 2006;23:46–52.
   PubMed Web of Science ®Google Scholar
• Albright ES, Desmond R, Bell DSH. Efficacy of Conversion from Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy. Diabetes Care. 2004;27:632–633.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Hirsch IB, Neifing JL. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639–643.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950–955.
   PubMed Web of Science ®Google Scholar
• Havelund S, Plum A, Ribel U. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–1504.
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Lüddeke HJ, Sreenan S. Safety and efficacy of insulin detemir in clinical practice: 14-Week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort. Int J Clin Pract. 2007;61:523–528.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Perry CM. Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2004;64:2577–2595.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel HC, Hompesch B. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635–642.
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–1112.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Roønn BB. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–1620.
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290–299.
   PubMed Web of Science ®Google Scholar
• De Leeuw I, Vague P, Selam JL. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7:73–82.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274.
   PubMed Web of Science ®Google Scholar
• Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine hagedorn (isophane) insulin in the treatment of diabetes: A systematic review. Diabetes Obes Metab. 2013;15:978–986. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority tr. Clin Ther. 2009;31:2086–2097.
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Simon ACR, Holleman F. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011:CD006383.
   PubMedGoogle Scholar
• Vargas-Uricoechea H. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. J Diabetes Res. 2018;2018:2052101.
   PubMed Web of Science ®Google Scholar
• Becker RHA, Dahmen R, Bergmann K. New insulin glargine 300 unitszm L21 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin Glargine 100 UnitszmL21. Diabetes Care. 2015;38:637–643.
   PubMed Web of Science ®Google Scholar
• Becker RHA, Nowotny I, Teichert L. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261–267.
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab. 2018;20:121–128.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Giaccari A. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20:541–548.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Harris SB, Baron H. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units/mL versus 100 Units/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care. 2018;41:1672–1680.
   PubMed Web of Science ®Google Scholar
• Díez-Fernández A, Cavero-Redondo I, Moreno-Fernández J. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2019;56:355–364.
   PubMed Web of Science ®Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–2114.
   PubMed Web of Science ®Google Scholar
• Heise T, Hövelmann U, Nosek L. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11:1193–1201.
   PubMed Web of Science ®Google Scholar
• Multi-Hexamer Formation Is the Underlying Mechanism behind the Ultra-Long Glucose-Lowering Effect of Insulin Degludec | American Diabetes Association.
   Google Scholar
• Heise T, Meneghini L. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20:75–83.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Hollander P, Miranda-Palma B. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–1162.
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Klonoff DC, Khunti K. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. 2020;63:698–710.
   PubMed Web of Science ®Google Scholar
• Del Prato S. How conclusive is the CONCLUDE trial? Diabetologia. 2020;63:692–697.
   PubMed Web of Science ®Google Scholar
• Lane W, Bailey TS, Gerety G. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes the SWITCH 1 randomized clinical trial. J Am Med Assoc. 2017;318:33–44.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bhargava A, Chaykin L. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes the SWITCH 2 randomized clinical trial. J Am Med Assoc. 2017;318:45–56.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Zhang XL, Xu B. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:429–441.
   PubMed Web of Science ®Google Scholar
• Korsatko S, Deller S, Koehler G. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515–521.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cheng A, Ritzel R. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head bright trial. Diabetes Care. 2018;41:2147–2154.
   PubMed Web of Science ®Google Scholar
• Miura H, Sakaguchi K, Otowa-Suematsu N. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study. Diabetes Obes Metab. 2020;22:2356-2363.
   Google Scholar
• Cai X, Gao X, Yang W. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017;18:1789–1798.
   PubMed Web of Science ®Google Scholar
• Davies M, Dahl D, Heise T. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34:1340–1353.
   PubMed Web of Science ®Google Scholar
• Biosimilar medicines: overview | european Medicines Agency.
   Google Scholar
• Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Jun 2014.
   Google Scholar
• Dongerkery SP, Schroeder PR, Shomali ME. Insulin and Its Cardiovascular Effects: what Is the Current Evidence? Curr Diab Rep. 2017;17:120.
   Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648–659. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Lucidi P, Porcellati F, Rossetti P. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: A randomized cross-over study. Diabetes Care. 2011;34:1312–1314.
   PubMed Web of Science ®Google Scholar
• Brange J, Owens DR, Kang S. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13:923–954.
   PubMed Web of Science ®Google Scholar
• Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and Pharmacodynamics of Basal Insulins. Diabetes Technol Ther. 2011;13:S-15-S-24.
   PubMed Web of Science ®Google Scholar
• Erpeldinger S, Rehman MB, Berkhout C. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016;16:39.
   Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–493.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Bosch J, Dagenais GR. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Marso SP, Mcguire DK, Zinman B. Efficacy and safety of degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377:723–732.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Patel RA, Merrill P. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Battelino T, Danne T. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21–39. John Wiley and Sons Ltd.
   PubMed Web of Science ®Google Scholar
• Nørgaard K, Sukumar N, Rafnsson SB. Efficacy and safety of rapid-acting insulin analogs in special populations with type 1 diabetes or gestational diabetes: systematic review and meta-analysis. Diabetes Ther. 2018;9:891–917.
   PubMed Web of Science ®Google Scholar
• Bode BW, Iotova V, Kovarenko M. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial. Diabetes Care. 2019;42:1255–1262. American Diabetes Association Inc.
   PubMed Web of Science ®Google Scholar
• EMA EPAR Fiasp.
   Google Scholar
• EMA EPAR Lyumjev.
   Google Scholar
• EMA EPAR Lantus.
   Google Scholar
• EMA EPAR Toujeo.
   Google Scholar
• EMA EPAR Levemir.
   Google Scholar
• EMA EPAR Tresiba.
   Google Scholar
• Toledano Y, Hadar E, Hod M. Safety of insulin analogues as compared with human insulin in pregnancy. Expert Opin Drug Saf. 2016;15:963–973.
   PubMed Web of Science ®Google Scholar
• Blumer I, Hadar E, Hadden DR. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4227–4249.
   PubMed Web of Science ®Google Scholar
• Lambert K, Holt RIG. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013;15:888–900. Blackwell Publishing Ltd.
   PubMedGoogle Scholar
• McCance DR, Casey C. Type 1 Diabetes in Pregnancy. Endocrinol Metab Clin North Am. 2019;48:495–509.
   PubMedGoogle Scholar
• FDA Lantus.
   Google Scholar
• O’Neill SM, Kenny LC, Khashan AS. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev. 2017;2:CD011880.
   Web of Science ®Google Scholar
• Van Bon AC, Bode BW, Sert-Langeron C. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther. 2011;13:607–614.
   PubMed Web of Science ®Google Scholar
• Kerr D, Wizemann E, Senstius J. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: A systematic review. J Diabetes Sci Technol. 2013;7:1595–1606. Diabetes Technology Society.
   PubMedGoogle Scholar
• Bode B, Garg S, Norwood P. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technol Ther. 2020;23:41-50.
   Google Scholar
• Klonoff DC, Evans ML, Lane W. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019;21:961–967.
   PubMed Web of Science ®Google Scholar
• Cameron CG, Bennett Bpharm HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ. 2009;180:400–407.
   PubMed Web of Science ®Google Scholar
• Shafie AA, Ng CH, Tan YP. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017;35:141–162.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Kristensen PL, Nørgaard K. Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Curr Med Res Opin. 2016;32:1719–1725.
   PubMed Web of Science ®Google Scholar
• Lee TY, Kuo S, Yang CY. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years. Br J Clin Pharmacol. 2020;86:852-860.
   Web of Science ®Google Scholar
• Johnson EL, Feldman H, Butts A. Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes. 2020;38:10–38.
   PubMedGoogle Scholar
• Hövelmann U, Brøndsted L, Kristensen NR. 237-OR: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes. 2020;69:237–OR.
   Google Scholar
• Kumar V, Choudhry I, Namdev A. Oral insulin: myth or reality. Curr Diabetes Rev. 2017;14:497–508.
   Web of Science ®Google Scholar
• Halberg IB, Lyby K, Wassermann K. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:179–188.
   PubMed Web of Science ®Google Scholar
• Mathieu C. Lancet diabetes endocrinol. Lancet. 2019;7:162–163. Publishing Group. Oral insulin: time to rewrite the textbooks.
   Google Scholar
• Caparrotta TM, Evans M. PEGylated insulin Lispro, (LY2605541)-A new basal insulin analogue. Diabetes Obes Metab. 2014;16:388–395. Blackwell Publishing Ltd
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Lunt H, Franek E. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1081–1088.
   PubMedGoogle Scholar
• Cusi K, Sanyal AJ, Zhang S. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab. 2016;18:50–58.
   PubMed Web of Science ®Google Scholar
• Muñoz-Garach A, Molina-Vega M, Tinahones FJ. How can a good idea fail? Basal insulin peglispro [LY2605541] for the treatment of type 2 diabetes. Diabetes Ther. 2017;8:9–22. Springer Healthcare.
   PubMedGoogle Scholar
• Tromans RA, Carter TS, Chabanne L. A biomimetic receptor for glucose. Nat Chem. 2019;11:52–56.
   PubMed Web of Science ®Google Scholar
• Traitel T, Cohen Y, Kost J. Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions. Biomaterials. 2000;21:1679–1687.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI, Armand M. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2:198–209.
   PubMed Web of Science ®Google Scholar
• Muchmore DB. The need for faster insulin: problem solved? J Diabetes Sci Technol. 2017;11:157–159. SAGE Publications Inc.
   PubMedGoogle Scholar
• Turner RC, Cull CA, Frighi V. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Dornhorst A, Sreenan S. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr Med Res Opin. 2009;25:2601–2608.
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Amiel SA, Bilous RW. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med. 2006;23:285–292.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. 2004;47:622–629.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): A prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2:553–561.
   PubMed Web of Science ®Google Scholar